Literature DB >> 23931012

Role of induction therapy: surgical resection of non-small cell lung cancer after induction therapy.

R Taylor Ripley1, Valerie W Rusch.   

Abstract

Patients with Stage III non-small cell lung cancer are best managed by multimodality therapy. Patients with N2 disease can be treated with induction therapy (usually chemotherapy) followed by surgical resection. Patients whose medical comorbidities preclude surgery should be treated with definitive chemoradiotherapy. T3 or T4 tumors involving the superior sulcus or spine are best managed with induction chemoradiotherapy and surgical resection.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Induction therapy; Stage III lung cancer; Surgery

Mesh:

Year:  2013        PMID: 23931012     DOI: 10.1016/j.thorsurg.2013.04.004

Source DB:  PubMed          Journal:  Thorac Surg Clin            Impact factor:   1.750


  10 in total

1.  Postoperative Radiotherapy for Surgically Resected ypN2 Non-Small Cell Lung Cancer.

Authors:  Whitney S Brandt; Wanpu Yan; Jonathan E Leeman; Kay See Tan; Bernard J Park; Prasad S Adusumilli; Matthew J Bott; Daniela Molena; James Isbell; Jamie Chaft; Andreas Rimner; David R Jones
Journal:  Ann Thorac Surg       Date:  2018-05-26       Impact factor: 4.330

2.  Distinct patterns of angiogenic factor expression as a predictive factor of response to chemotherapy in stage IIIA non-small-cell lung cancer patients.

Authors:  Nikolaos Koufos; John Syrios; Despina Michailidou; Ioannis D Xynos; Andreas Lazaris; Nicolaos Kavantzas; Periclis Tomos; Stamatis Kakaris; Christos Kosmas; Nikolas Tsavaris
Journal:  Mol Clin Oncol       Date:  2016-07-27

3.  Postinduction positron emission tomography assessment of N2 nodes is not associated with ypN2 disease or overall survival in stage IIIA non-small cell lung cancer.

Authors:  R Taylor Ripley; Kei Suzuki; Kay See Tan; Prasad S Adusumilli; James Huang; Bernard J Park; Robert J Downey; Nabil P Rizk; Valerie W Rusch; Manjit Bains; David R Jones
Journal:  J Thorac Cardiovasc Surg       Date:  2015-10-19       Impact factor: 5.209

4.  Adding radiation to induction chemotherapy does not improve survival of patients with operable clinical N2 non-small cell lung cancer.

Authors:  Chi-Fu Jeffrey Yang; Brian C Gulack; Lin Gu; Paul J Speicher; Xiaofei Wang; David H Harpole; Mark W Onaitis; Thomas A D'Amico; Mark F Berry; Matthew G Hartwig
Journal:  J Thorac Cardiovasc Surg       Date:  2015-07-02       Impact factor: 5.209

Review 5.  Lung cancer surgery: an up to date.

Authors:  Nikolaos Baltayiannis; Michail Chandrinos; Dimitrios Anagnostopoulos; Paul Zarogoulidis; Kosmas Tsakiridis; Andreas Mpakas; Nikolaos Machairiotis; Nikolaos Katsikogiannis; Ioanna Kougioumtzi; Nikolaos Courcoutsakis; Konstantinos Zarogoulidis
Journal:  J Thorac Dis       Date:  2013-09       Impact factor: 2.895

Review 6.  Surgery in 2013 and beyond.

Authors:  Rishendran Naidoo; Morgan N Windsor; Peter Goldstraw
Journal:  J Thorac Dis       Date:  2013-10       Impact factor: 2.895

Review 7.  Surgical strategies in the therapy of non-small cell lung cancer.

Authors:  Feras Al-Shahrabani; Daniel Vallböhmer; Sebastian Angenendt; Wolfram T Knoefel
Journal:  World J Clin Oncol       Date:  2014-10-10

8.  [Occlusion with Bronchial Covered Stent in the Management of Bronchial Stump Fistula after Right Middle and Lower Lobectomy: A Case Report and Literature Review].

Authors:  Miao Huang; Fangliang Lu; Shaolei Li; Yuquan Pei; Liang Wang; Yue Yang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2021-04-20

Review 9.  Resectable IIIA-N2 Non-Small-Cell Lung Cancer (NSCLC): In Search for the Proper Treatment.

Authors:  Debora Brascia; Giulia De Iaco; Marcella Schiavone; Teodora Panza; Francesca Signore; Alessandro Geronimo; Doroty Sampietro; Michele Montrone; Domenico Galetta; Giuseppe Marulli
Journal:  Cancers (Basel)       Date:  2020-07-25       Impact factor: 6.639

10.  Major pulmonary resection after neoadjuvant chemotherapy or chemoradiation in potentially resectable stage III non-small cell lung carcinoma.

Authors:  Michael Peer; Sharbel Azzam; Arnold Cyjon; Rivka Katsnelson; Henri Hayat; Ilan Bar; Ofer Merimsky
Journal:  Sci Rep       Date:  2021-10-12       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.